A First Report of Endoscopic Ultrasound for the Diagnosis of Pancreatic Amyloid Deposition in Immunoglobulin Light Chain (AL) Amyloidosis (Primary Amyloidosis)

Krishna, Somashekar G.; Bhutani, Manoop S.; Mosher, Charles H.; Staerkel, Gregg; Weston, Brian

doi:10.6092/1590-8577/1505

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, our study is the largest series of EBUS-TBNA/EUS-FNA-detected amyloid deposits in LNs and with amyloid subtyping by MS possible in all cases. There are several reports of other organ sites in which amyloid was diagnosed by FNA, [38][39][40][41] but only one, an amyloidoma of the stomach, that was subtyped by MS analysis. 41 Lack of awareness is likely at least one reason for this.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of EBUS‐TBNA/EUS‐FNA and mass spectrometry for diagnosis and typing of lymph node amyloidosis: 10‐year experience in two tertiary care academic centers

Naqvi,

Bonert,

Finley

et al. 2023

Cancer Cytopathology

View full text Add to dashboard Cite

BackgroundThe objectives of this study were to investigate the utility of endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA)/endoscopic ultrasound‐guided fine‐needle aspiration (EUS‐FNA) for the diagnosis of amyloidosis coupled with the feasibility of mass spectrometry (MS) for amyloid subtyping.MethodsAll patients who had amyloid diagnosed by EBUS‐TBNA/EUS‐FNA at two tertiary care centers from 2011 to 2020 were retrieved along with the MS subtype, clinical findings, and outcomes.ResultsEight patients were included: seven underwent EBUS‐TBNA of mediastinal lymph nodes, and one underwent EUS‐FNA of a periportal lymph node. Ages ranged from 37 to 79 years (median, 69 years), with equal numbers of men and women. Presenting clinical history included one case each of follicular lymphoma, lymphoplasmacytic lymphoma, rheumatoid arthritis, possible sarcoid, cirrhosis, and chronic renal insufficiency, and one case each of suspected pulmonary and cardiac amyloidosis. All cases showed waxy, amorphous material on direct smears (n = 5) or ThinPrep slides (n = 3), which were confirmed as amyloid on Congo Red staining. Immunohistochemistry showed dominant lambda staining in two of three cases. MS was performed in all cases and identified five of the light‐chain (AL) type, one of the heavy‐chain/AL type, and two suggestive of AL amyloidosis. Bone marrow biopsy performed in seven patients demonstrated that three had monoclonal plasma cells and one had lymphoplasmacytic lymphoma. Two of four patients with systemic amyloidosis received chemotherapy and remained alive, whereas three with localized disease remained stable under observation.ConclusionsEBUS‐TBNA/EUS‐FNA is effective for amyloidosis diagnosis and provides adequate material for ancillary tests, including MS, which can identify the precursor amyloidogenic protein, leading to appropriate patient management.

show abstract

Section: Discussionmentioning

confidence: 99%

“…To date, EUS-FNAbased diagnosis of amyloidosis has been limited to a few case reports involving the stomach, duodenum, and pancreas. 40,41,[56][57][58] There are also two reports of abdominal nodal amyloidosis diagnosed by EUS-FNA. 36,37 It is not clear whether all of these reported cases were localized or systemic.…”

Section: Discussionmentioning

confidence: 99%